ArticlePloS one2015
Pharmacist-Led Medication Reviews to Identify and Collaboratively Resolve Drug-Related Problems in Psychiatry - A Controlled, Clinical Trial.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Prevalence and solving strategies of drug-related problems in adult psychiatric inpatients - a systematic review.Frontiers in psychiatry · 2024Pooled it
- Clinical and economic outcomes of hospital pharmaceutical care: a systematic review and meta-analysis.BMC health services research · 2020Pooled it
- Effectiveness of medication reviews in identifying and reducing medication-related problems among people with intellectual disabilities: A systematic review.Journal of applied research in intellectual disabilities : JARID · 2019Pooled it
- Professional, structural and organisational interventions in primary care for reducing medication errors.The Cochrane database of systematic reviews · 2017Pooled it
- Interprofessional Medication Management in Patients With Multiple Morbidities.Deutsches Arzteblatt international · 2016Trial
- Trial
- Developing a core competency framework for psychiatric pharmacists: a Europe-wide e-Delphi consensus study conducted by the European Society of Clinical Pharmacy Mental Health Special Interest Group.International journal of clinical pharmacy · 2026Article
- Medication discrepancies and medication-related problems in psychiatric patients: A medication reconciliation study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Developing the Inpatient Mental Health Pharmaceutical Assessment and Care Tool (IMPACT) for use by UK mental health pharmacy teams-a modified Delphi study.British journal of clinical pharmacology · 2025Article
- Exploring current approaches towards patient prioritisation for clinical pharmacy services in UK mental health inpatient care.BMC psychiatry · 2025Article
- Pharmacist-assisted implementation of guideline recommendations for QTc monitoring during psychopharmacotherapy - a prospective, randomized feasibility study.Frontiers in psychiatry · 2025Article
- Assessing the Risk of QT Prolongation in a Psychiatric Inpatient Cohort: A Retrospective Cross-Sectional Study.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Med rec double check: Inpatient psychiatry medication errors identified on admission using Medicaid Web portals and electronic pharmaceutical claims data.The mental health clinician · 2024Article
- Reduced prevalence of drug-related problems in psychiatric inpatients after implementation of a pharmacist-supported computerized physician order entry system - a retrospective cohort study.Frontiers in psychiatry · 2024Article
- Incorporation of a specialist mental health clinical pharmacist within a primary care network: patient referrals, prescribing decisions, and clinical outcomes.Therapeutic advances in psychopharmacology · 2024Article
- Article
- Pharmacogenetic-Guided Antidepressant Selection as an Opportunity for Interprofessional Collaboration: A Case Report.Life (Basel, Switzerland) · 2021Article
- General practitioner practice-based pharmacist input to medicines optimisation in the UK: pragmatic, multicenter, randomised, controlled trial.Journal of pharmaceutical policy and practice · 2021Article
- Impact of pharmacists on outcomes for patients with psychiatric or neurologic disorders.The mental health clinician · 2020Article
- Impact of a specialist mental health pharmacy team on medicines optimisation in primary care for patients on a severe mental illness register: a pilot study.European journal of hospital pharmacy : science and practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aim of the studyThis prospective, controlled trial aimed to assess the effect of pharmacist-led medication reviews on the medication safety of psychiatric inpatients by the resolution of Drug-Related Problems (DRP). Both the therapy appropriateness measured with the Medication Appropriateness Index (MAI) and the number of unsolved DRP per patient were chosen as primary outcome measures.
methodsDepending on their time of admission, 269 psychiatric patients that were admitted to a psychiatric university hospital were allocated in control (09/2012-03/2013) or intervention group (05/2013-12/2013). In both groups, DRP were identified by comprehensive medication reviews by clinical pharmacists at admission, during the hospital stay, and at discharge. In the intervention group, recommendations for identified DRP were compiled by the pharmacists and discussed with the therapeutic team. In the control group, recommendations were not provided except for serious or life threatening DRP. As a primary outcome measure, the changes in therapy appropriateness from admission to discharge as well as from admission to three months after discharge (follow-up) assessed with the MAI were compared between both groups. The second primary outcome was the number of unsolved DRP per patient after completing the study protocol. The DRP type, the relevance and the potential of drugs to cause DRP were also evaluated.
resultsThe intervention led to a reduced MAI score by 1.4 points per patient (95% confidence interval [CI]: 0.8-2.0) at discharge and 1.3 points (95% CI: 0.7-1.9) at follow-up compared with controls. The number of unsolved DRP in the intervention group was 1.8 (95% CI: 1.5-2.1) less than in control.
conclusionThe pharmaceutical medication reviews with interdisciplinary discussion of identified DRP appears to be a worthy strategy to improve medication safety in psychiatry as reflected by less unsolved DRP per patient and an enhanced appropriateness of therapy. The promising results of this trial likely warrant further research that evaluates direct clinical outcomes and health-related costs.
trial registrationDeutsches Register Klinischer Studien (DRKS), DRKS00006358.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.